A23. LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD

885

微信好友朋友圈 QQ好友复制链接

查看最新文献

发文信息

A23. LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD - 最新文献

查看全部

New Quantitative Metric for Identifying Fibrosis Predicts Lung Cancer Outcomes in the National Lung Screening Trial

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1109 J.M. Wang, S. Bose, S. Murray, W. Labaki, K. Flaherty, M. Han, C. Hatt

Effects of Nintedanib on Circulating Biomarkers in Patients With Progressive Pulmonary Fibrosis: Subgroup Analyses of the INBUILD Trial

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1128 T. M. Maher, R. Jenkins, F. Bonella, S. Assassi, I. Noth, C. Diefenbach, C. Ittrich, K. Rohr, M. Kolb, on behalf of the INBUILD trial investigators

Associations Between Semi-quantitative HRCT Features and Outcomes in Patients With IPF: Data From the INPULSIS Trials

Pub Date : 2023-05-01 DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1122 J. Jacob, A. Wells, N. Sverzellati, L. Richeldi, E. Bendstrup, S. Stowasser, D. Lievens, W. Stansen, V. Cottin

免责声明：
本页显示期刊或杂志信息，仅供参考学习，不是任何期刊杂志官网，不涉及出版事务，特此申明。如需出版一切事务需要用户自己向出版商联系核实。若本页展示内容有任何问题，请联系我们，邮箱：info@booksci.cn，我们会认真核实处理。